Ekspositionen for didanosin eller dets aktive metabolit (dideoxiadenosin 5 ’ - triphosphat) øges in vitro, når didanosin administreres sammen med ribavirin.
Exposure to didanosine or its active metabolite (dideoxyadenosine 5’ -triphosphate) is increased in vitro when didanosine is co- administered with ribavirin.